Loading people...
Felice Verduyn - van Weegen is a Partner at EQT Life Sciences, a global investment organization focused on advancing healthcare innovation. She is instrumental in identifying and investing in groundbreaking companies within the life sciences sector.
Felice Verduyn - van Weegen invests in a wide range of life sciences companies, including those in biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions. Her focus is on innovative companies with strong scientific foundations that address unmet medical needs.
Felice Verduyn - van Weegen works as a Partner at EQT Life Sciences, which is a specialized investment platform within the global EQT organization.
Felice Verduyn - van Weegen is a Partner at EQT Life Sciences based in Amsterdam, North Holland, in the Netherlands. Before assuming her current position, she spent seven years as an investor at Life Sciences Partners (LSP) from 2015 until its formal acquisition by the EQT Group in 2022. Earlier in her professional career, she worked as a consultant at McKinsey & Company, where she initially developed her strategic expertise in the European healthcare and biotechnology sectors. Leveraging an academic background in biomedical sciences and over a decade of direct experience in venture capital and private equity, she currently serves on the board of directors for multiple European life sciences portfolio companies. Her primary investment focus centers on funding and actively supporting early-stage biomedical and healthcare companies from their initial clinical development stages through their final commercialization phases.
Felice Verduyn - van Weegen is a distinguished Partner at EQT Life Sciences, a specialized investment platform within the global EQT organization. EQT Life Sciences is renowned for its commitment to investing in and developing companies that are at the forefront of medical and scientific breakthroughs. As a Partner, Felice plays a critical role in shaping the firm's investment strategy and portfolio, leveraging her deep industry expertise to identify opportunities with high growth potential and transformative impact.
Her investment focus at EQT Life Sciences spans a broad spectrum of the life sciences landscape. This includes, but is not limited to, biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions. Felice is particularly interested in companies that possess robust scientific foundations, innovative technologies, and clear pathways to address unmet medical needs. She seeks out ventures that are poised to disrupt existing paradigms, improve patient outcomes, and contribute significantly to the evolution of global healthcare.
Felice's career background is characterized by a strong blend of scientific acumen and financial expertise, positioning her uniquely to evaluate complex life science investments. Prior to her role at EQT Life Sciences, she cultivated extensive experience within the healthcare and investment sectors, likely holding positions that honed her analytical skills and understanding of market dynamics. This background enables her to not only assess the scientific validity of new technologies but also to evaluate their commercial viability and strategic fit within the broader healthcare ecosystem. Her journey reflects a dedication to fostering innovation and translating scientific discovery into tangible patient benefits.
While specific notable investments are often confidential or attributed to the firm as a whole, Felice Verduyn - van Weegen is integral to EQT Life Sciences' success in building a portfolio of leading companies. She contributes to the firm's track record of backing ventures that have gone on to achieve significant milestones, from successful clinical trials to market launches and strategic exits. Her work involves rigorous due diligence, strategic guidance for portfolio companies, and active engagement with management teams to accelerate their growth and achieve their full potential. Through her leadership, EQT Life Sciences continues to make impactful investments that drive progress in the life sciences industry.
